Septerna Initiates Phase 1 Trial for Oral Hypoparathyroidism Drug SEP-479, First Participants Dosed
summarizeSummary
Septerna announced the initiation of a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist designed to treat hypoparathyroidism, with the first participants now dosed. This marks a significant step forward for the company's pipeline, moving a key drug candidate into human trials. For a clinical-stage biotechnology company, advancing a drug into Phase 1 is a critical de-risking event that validates preclinical work and establishes a new clinical asset. The potential for a once-daily oral therapy could offer a significant advantage over existing treatments for hypoparathyroidism. Investors will now be watching for initial data from this trial, which is anticipated in late 2026 or early 2027.
At the time of this announcement, SEPN was trading at $23.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $4.66 to $32.63. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.